* TFF Pharmaceuticals Inc reported a quarterly adjusted loss of $2.01 per share for the quarter ended in December, higher than the same quarter last year, when the company reported EPS of $-2.50. The mean expectation of two analysts for the quarter was for a loss of $2.12 per share. Wall Street expected results to range from $-2.35 to $-1.89 per share.
* Revenue fell 63.5% to $114.33 thousand from a year ago; analysts expected $100.00 thousand.
* TFF Pharmaceuticals Inc's reported EPS for the quarter was a loss of $2.01.
* The company reported a quarterly loss of $4.76 million.
* TFF Pharmaceuticals Inc shares had fallen by 6.1% this quarter.
FORECAST CHANGES
* The mean earnings estimate of analysts was unchanged in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* Wall Street's median 12-month price target for TFF Pharmaceuticals Inc is $34.50
This summary was machine generated from LSEG data March 28 at 09:13 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 -2.12 -2.01 Beat
Sep. 30 2023 -2.87 -2.25 Beat
Jun. 30 2023 -4.75 -3.50 Beat
Mar. 31 2023 -5.75 -4.75 Beat
Comments